LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1 -5.66

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.99

Max

1.02

Belangrijke statistieken
By Trading Economics
Inkomsten	614K -6.5M
Werknemers	37

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+292.16% upside

Dividenden
By Dow Jones
Volgende Winsten	30 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-25M 79M
Vorige openingsprijs	6.66
Vorige sluitingsprijs	1

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mrt 2026, 17:33 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mrt 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mrt 2026, 16:03 UTC

Belangrijke Nieuwsgebeurtenissen

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mrt 2026, 14:50 UTC

Belangrijke Marktbewegers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mrt 2026, 14:37 UTC

Acquisities, Fusies, Overnames

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mrt 2026, 14:29 UTC

Belangrijke Nieuwsgebeurtenissen

EU Finance Ministers Tally Economic Hit of Iran War -- Update

28 mrt 2026, 13:32 UTC

Winsten

Berkshire Hathaway Just Notched an 8-Day Losing Streak. It's a Good Time to Get Exposure to the Conglomerate. -- Barrons.com

28 mrt 2026, 08:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

28 mrt 2026, 08:00 UTC

Winsten

It Was a Busy Week for Videogames. Keep An Eye on These Stocks. -- Barrons.com

27 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 19:16 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mrt 2026, 19:07 UTC

Marktinformatie

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mrt 2026, 19:04 UTC

Marktinformatie

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mrt 2026, 19:03 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 19:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mrt 2026, 18:12 UTC

Marktinformatie

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mrt 2026, 17:34 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mrt 2026, 17:29 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mrt 2026, 16:38 UTC

Marktinformatie

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mrt 2026, 16:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mrt 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 15:43 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mrt 2026, 14:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mrt 2026, 14:26 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

292.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 292.16%

Hoogste 4 USD

Laagste 4 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.